In re application of:

Giblin et al.

10/574886 IAP9 Reg'd PCT/PTO 07 APR 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:		To Be Assigned	Group Art Unit:					
File Date:		Concurrently Herewith	Examiner:					
For:		Cyclohexene Compounds						
P.O.	Box 14	the U.S. Patent and Trademark Office 150 , VA 22313-1450						
		INFORMATION DISCLO	SURE STATEMENT					
		ants request that the references identified on Form and officially made of record in accordance with the	n PTO-1449 appended hereto be considered by the e provisions of 37 CFR 1.97					
Ī] Co X] A c PC Re	pies of the references are enclosed: References 5 pies of the references were submitted in parent appropriate opposed in the references were submitted in parent appropriate of the International Search Report which is submitted herewith. All of apport are listed on the attached form PTO-1449 and the U.S. Patent Office by the International Bureau	plication (37 CFR 1.98(d)) ued on International Application No. the publications cited in the International Search d Applicants understand that copies have been supplied					
A. [-	filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR []		ubmitted herewith is being filed before the mailing of a Request For Continued Examination under 37					
В. []	filing date of the above application or the date						
	[]	Applicant hereby certifies that each item of info Statement was cited in a communication from a application not more than three months prior to						
	[]	Applicant elects the option to pay the fee set fort Disclosure Statement under § 1.97(c) (\$180.00).	h in 37 CFR 1.17(p) for submission of an Information					
C. []	1.113, or a notice of allowance under § 1.311, v	ed herewith is being filed after a final action under § whichever occurs first, but before the payment of the ational Search Report which Issued on International					
I	n acco	rdance with the requirements of 37 CFR 1.97(d):						

10/574886 IAP9 Rec'd PCMPTO 0 7 APR 2006

Applicant hereby certifies that each item of information contained in this Information Disclosure [] Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Applicant hereby petitions for the consideration of the accompanying Information Disclosure [] Statement. 37 CFR 1.97(d)(ii). The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith. [] [X] Please charge any required fees to Deposit Account No.07-1392. [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Registration No. 45,582

Date: April & Zoo6
GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8160 Facsimile: (919) 483-7988

10/574886 AP9 Rec'd PCT/PTO 07 APR 2006

								SI	heet 1 of 2	
Form PTO-1449		U.S. Department of Commerce		rce	ATTY DOCKET NO. SERIAL NO.					
		Patent and Trademark Office		fice	PB60532USW	To Be Assigned				
		IATION DISCLOSURE			APPLICANT Giblin et al.					
S1		MENT BY AP everal sheets if ne			FILING DATE Concurrently Herewith	GROUP				
			U.S. PA	ATEI	NT DOCUMENTS					
Examiner Initials		Document Number	Date	_	Name	Class	Subclass	Filing Date If Appropriate		
	1	US-5 663 180-A	02 -09 -1997 F	Reitz	DB et al.					
	2	US-5 723 483-A	03 -03 -1998 L	abee	euw et al.					
	3	US-5 811 459-A	09 -22 -1998 B	Breau	It et al					
	;	·' ,	Ç. * = -	_						
	4	US-6 492 411-B1	12 -10 -2002 T	alley	et al.					
	1		FOREIGI	N PA	ATENT DOCUMENTS	<u>.</u>	<u> </u>			
		Document Number	Date		Country	Class	Subclass	Tra Yes	nslation No	
	5	EP-0 647 629-A	04 -12 -1995 E	Р				XAL	ostract	
	6	EP-0 752 421-A	01 -08 -1997 E	P						
	7	EP-1 270 559-A	01 -02 -2003 E	P						
	8	WO-01/19814-A	03 -22 -2001 _V	vo						
,	9	WO-03/084917-A	10 -16 -2003 V	٧O			T			
	10	WO-2004/083185- A2	09 -30 -2004 _V	vo						
		OTHER D	OCUMENTS (Inclu	ding	Author, Title, Date, Pertinent Pa	ges, Etc)				
,	in -	Pathanetalou	rnal of the Institution o	of Ch	emists (India); 72 (5); 190-191;					
	12	KARIG GUNTER; Directed Deprotonation-Transmetalation as a Route to Substituted Pyridines; Organic Letters; 2001; 3 (6); 835-838;								
	1.3	PATHAN M D ET AL; 514183; Chemical Abstracts Service; 2001;								
	14	RAHIM ABDUR M ET AL; Isomeric acetoxy analogues of rofecoxib: A novel class of highly potent and selective cyclooxygenase-2 inhibitors; Bioorganic and Medicinal Chemistry Letters; 2002; 12 (19); 2753-2756;								
	15	REBSTOCK ANNE-SOPHIE; Synthesis and deprotonation of 2-(pyridyl)phenols and 2-(pyridyl)anilines; Organic and Biomolecular Chemistry; 2003; 17; 3064-3068;							liomolecular	
	16	TRIVEDI G S ET AL	; Indian Journal of Che	emist	ry; 1992; 31B; 366-369;					
Examiner	Signature	e		Da	ate Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IAPO ROC OPCTIPTO 27 APR 2006

Sheet 2 of 2

orm PTO-1	449	U.S. Department of Commerce		CE ATTY DOCKET NO.	ATTY DOCKET NO. SERIAL NO.				
Patent and Trademark Office		CE PB60532USW APPLICANT	PB60532USW To be Assigned						
INF	ORM	ATION DISC	LOSURE	Giblin et al.					
			FILING DATE Concurrently Herewith	GROUP	GROUP				
			U.S. PA	TENT DOCUMENTS					
Examiner Initials	Document Number		Date	Name	Class	Subclass	Filing Date If Appropriate		
								2	
						-			
			FOREIGN	PATENT DOCUMENTS					
		Document Number	Date	Country	Class	Subclass	Translation Yes No		
	17	WO-03/101959-A1	12 -11 -2003 V	VO		<u> </u>	$\downarrow - \downarrow$		
			-						
		OTHER D	OCUMENTS (Inclu	ding Author, Title, Date, Pertind	ent Pages, Etc))			
	18	ROSENBERG SAU Chemistry; 1984; 49	JL H ET AL; Convergen 9 (1); 56-62;	t and efficient synthesis of spiro[ber	nzofuran-3(2H),4'-	-piperidines]	; Journal o	r Organic	
									
Examiner S	ignature			Date Considered					
EXAMINER: I	nitial if ref	erence considered, w	hether or not citation is next communication to	in conformance with MPEP 609. Di	raw line through	citation if no	t in confor	nance and	